Gilead Sciences (GILD) Liabilities and Shareholders Equity (2009 - 2026)

Gilead Sciences (GILD) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $49.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 11.41% year-over-year to $49.4 billion; the trailing twelve-month figure through Jun 2026 stood at $223.2 billion (down 1.1% YoY), and the FY2025 full-year result was $59.0 billion, changed 0.05% from the prior year.
• Liabilities and Shareholders Equity slipped to $49.4 billion in Q2 2026 per GILD's latest filing, from $56.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $63.2 billion in Q4 2022 and bottomed at $49.4 billion in Q2 2026.
• Historically, Liabilities and Shareholders Equity has averaged $58.8 billion across 5 years, with a median of $59.0 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity fell 14.05% in 2024, then climbed 7.35% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $63.2 billion in 2022, then decreased by 1.66% to $62.1 billion in 2023, then fell by 5.04% to $59.0 billion in 2024, then increased by 0.05% to $59.0 billion in 2025, then declined by 16.37% to $49.4 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $49.4 billion, $56.3 billion, and $59.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.